{
  "source": "PA-Med-Nec-Qelbree.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2270-6\nProgram Prior Authorization/Medical Necessity\nMedication Qelbree® (viloxazine)*\nP&T Approval Date 9/1/2021, 2/2022, 6/2022, 7/2023, 7/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nQelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of attention deficit\nhyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older. The American\nAcademy of Pediatrics generally recommends stimulants as first-line medications for the treatment of\nADHD. Selective norepinephrine reuptake inhibitors (e.g. atomoxetine) and selective alpha-2\nadrenergic agonists (e.g. clonidine extended-release, guanfacine extended-release) are also\nrecommended, however the data are less robust.\n2. Coverage Criteriaa:\nA. Authorization\n1. Qelbree* will be approved based on both of the following:\na. One of the following:\n(1) History of failure, contraindication, or intolerance to both of the following (document\nmedication names and dates of trials):\n(a) a methylphenidate class stimulant (e.g. generic Concerta)\n(b) an amphetamine class stimulant (e.g. generic Adderall XR)\n-OR-\n(2) History of a substance use disorder or concern for potential misuse and/or diversion\n-AND-\nb. One of the following:\n(1) History of failure, contraindication, or intolerance to both of the following:\n(a) an alpha-2 adrenergic agonist [e.g. clonidine extended-release, guanfacine\nextended-release (document medication name and date of trial)].\n(b) atomoxetine [(generic Strattera) document date of trial]\n-OR-\n(2) Both of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(a) Patient is unable to swallow a solid dosage form (i.e. an oral tablet or capsule)\ndue to age, oral/motor difficulties, or dysphagia\n(b) History of failure, contraindication, or intolerance to Onyda XR (document date\nof trial).\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory require",
    "ia\n(b) History of failure, contraindication, or intolerance to Onyda XR (document date\nof trial).\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n* Qelbree is typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc; April 2022.\n2. Wolraich ML. et. al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of\nAttention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. Oct. 2019,\n144 (4) 2019-2528.\nProgram Prior Authorization/Medical Necessity – Qelbree (viloxazine)\nChange Control\n9/2021 New program.\nChange program type from Non-Formulary (program number 1368) to\n2/2022\nMedical Necessity (program number 2270).\nRemoved requirement that patient is less than 18 years old due to new\n6/2022\nFDA approval for adult patients.\n7/2023 Annual review. Updated examples to generics.\n7/2024 Annual review. No changes.\nAdded trial of Onyda XR for patients unable to swallow solid dosage\n1/2025\nform.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}